Oral presentation highlights TNX-102 SL (sublingual cyclobenzaprine HCl) treatment in Phase 3 RESILIENT study demonstrating statistically significant improvement in fibromyalgia…
First Solid Tumor Patient Treated with Second, Higher Dose in Phase 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction and Continued…
LP-20 contrast agent designed to diagnose interstitial cystitis and detect bladder cancerNovel MRI contrast agent, which received support from National…
Hevolution Foundation and Dolby Family Ventures join ND Capital as additional institutional investors bringing Series A funding to a total…
Oslo, August 21, 2024: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces its…
TARRYTOWN, N.Y., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and…
NEW YORK, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company,…
REDWOOD CITY, Calif., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced…
The clinically validated, unified platform aims to move beyond just therapy to deliver easy-to-use, real-time prevention, treatment, and maintenance for…
Clario's third annual ESG report for the calendar year 2023 highlights advancements in responsible artificial intelligence (AI), employee program investments,…